We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
The company is a professional pharmaceutical intermediate, API production and sales of enterprises, the main products are gatifloxacin series, levofloxacin series, sarafloxacin, praziquantel, gatifloxacin, gatifloxacin, oxyfluorocarboxylic acid, etc.
The company has domestic advanced production technology and modern production facilities, perfect testing equipment and scientific research and development talents. The production management team has 10 years of industry experience to ensure product quality and production stability, and has good cooperation and development prospects.
Hubei Xingjiu Pharmaceutical Co., Ltd. is located at No. 88 Hexi Avenue, Xisai mountain area, Huangshi City, Hubei Province. The company has four departments including production department, technology department, finance department and safety and environmental protection department. It has 4 technical backbones, more than 20 production operation backbones and more than 40 employees.
Hubei Xingjiu Pharmaceutical Co., Ltd. adheres to the business tenet of "survival by quality and development by reputation". It is sincere, innovative and keeps pace with the times. It is enthusiastic to join hands with all parties to create a bright future for the pharmaceutical industry.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
![Diacetato{(R)-5,5'-bis[di(3,5-di-t-butyl-4-methoxyphenyl)phosphino]-4,4'-bi-1,3-benzodioxole}rutheni](https://eimg.pharmasources.com/image/product/20240614/55584ed889430fc3fccca2f1c3e98283jpg!145)
